Retension Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 11.83 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 98.56M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.
Details
| Name | Retension Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 12 |
| Founded | 2023 |
| Ipo Date | 2026-10-09 |
| Ceo | Eric Keller |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 12.00 |
| Isin | US76135H1005 |
| Cusip | 76135H100 |
| Cik | 2002988 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Eric Keller, J.D. | Chief Executive Officer and Director |
| Alex Schwartz | Chief Financial Officer |
| Paul Sweetnam, Ph.D. | Chief Scientific Officer |
| Alison D. Schecter, M.D. | Chief Medical Officer |
| Sabine Bisson, Ph.D. | Chief Operating Officer |
| Michael Joseph Berendt, Ph.D. | Executive Chairman |
| Franklin M. Berger | Director |
| Donald Olds, M.B.A. | Director |
Contact
| Address | 1104 West Broad Street #1029, Falls Church, Virginia 22046, United States |
| Phone | (703) 940-9761 |
| Website | https://www.retensionpharmaceuticals.com |